Guardant Health won FDA approval for an upgraded Guardant360 Liquid CDx, positioning the test to expand comprehensive tumor profiling beyond the company’s prior assay footprint. Guardant said the new blood-based platform analyzes a genomic footprint 100-fold larger than earlier Guardant360 versions and transfers seven existing FDA-approved CDx indications to the upgraded test.